Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

FIEBRE aims to design new evidence-based guidelines to manage fever, thereby ensuring that patients get drugs that give them the best chance of recovery, and thereby help stop the spread of antimicrobial resistance (AMR), a major global health problem.

Pills and tablets

On 8 March 2018, the London School of Hygiene & Tropical Medicine (LSHTM) announced the start of a major new global study, the 4-year Febrile Illness Evaluation in a Broad Range of Endemicities (FIEBRE) project.

By identifying the leading causes of fever in sub-Saharan Africa and Asia and how fever patients are cared for, FIEBRE aims to design new evidence-based guidelines to manage fever, thereby ensuring that patients get drugs that give them the best chance of recovery, and thereby help stop the spread of antimicrobial resistance (AMR), a major global health problem.

Funded by UKAid from DFID, FIEBRE will be conducted by LSHTM with the Liverpool School of Tropical Medicine, the Universities of Oxford, Barcelona, and Otago, as well as partner institutions within five study countries – Laos, Malawi, Mozambique, Myanmar and Zimbabwe.

MORU’s Lao PDR Unit, LOMWRU, and the Microbiology Laboratory team within Mahosot Hospital, Vientiane, will work with Vientiane Provincial Hospital for the Laos arm of this multicentre study. In addition, Yoel Lubell of MORU MAEMOD will coordinate the biomarker investigations, so that by its end, the study will have a better idea as to which biomarkers best distinguish between viral and bacterial infections, and which (if any) can predict severe outcomes.

“There is an urgent need to understand the aetiologies of fevers across Asia and Africa with consensus protocols to facilitate between country comparisons, that have so far eluded us, to inform patient treatment policies,” explained Oxford Prof Paul Newton, LOWMRU Director. “We will work to recruit and diagnose inpatients and outpatients to improve our understanding of the causes of fever in the Mekong River valley and how these compare with other countries and to work for these results to be translated into health policy.”

David Mabey, Professor of Communicable Diseases at the LSHTM and Principal Investigator of the FIEBRE project, said: “The world has made great strides in tackling malaria. Surprisingly, there has been limited research on other potential causes of febrile illness, such as infections by bacteria, viruses, and fungi, and the WHO does not provide specific guidance on the management of non-malarial fevers.

“We want to identify the treatable and preventable causes of fever in children and adults in Africa and Asia, and to identify those most at risk of different infections. Our goal is to develop guidelines that can be a blueprint for the effective management of patients with fever in different settings.”

Read the full LSHTM story announcing the FIEBRE study Major new project to reveal leading causes of fever in sub-Saharan Africa and Asia.

Similar stories

RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19

@Oxford Research

Convalescent plasma has been widely used as a treatment for COVID-19 but to date there has been no convincing evidence of the effect of convalescent plasma on clinical outcomes in patients admitted to hospital with COVID-19. Recruitment to the convalescent plasma arm of the RECOVERY trial has now closed. The preliminary analysis based on 1873 reported deaths among 10,406 randomised patients shows no significant difference in the primary endpoint of 28-day mortality. Recruitment to all other treatment arms – tocilizumab, aspirin, colchicine, and Regeneron’s antibody cocktail – continues as planned.

Check-list recommended to improve reporting of microscopy methods and results in malaria studies

@Oxford MORU Publication Research

A study to explore the variations of how microscopy methods are reported in published malaria studies has recommended standardised procedures should be implemented for methodological consistency and comparability of clinical trial outcomes.

Receiving and responding to community feedback during health system crises in Kenya

KWTRP Publication Research

The responsiveness of a health system is one of its goals, alongside fairness in financing and outcomes. Listening and responding to the public can make a health system stronger and fairer. However, responsiveness is likely to be undermined, especially for vulnerable and marginal populations, in periods of crises such as disease outbreaks. In the current COVID-19 crisis, there has been more focus on health system control interventions, with minimal consideration of community views. KWTRP colleagues in Kenya consider community engagement and citizens feedback channels, concerns raised by the public and how they were handled, and highlight lessons learned.

RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

@Oxford Research

Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.

The COVID-19 vaccine: do we know enough to end the pandemic?

@Oxford MORU

Blog by Rima Shretta. Preliminary efficacy results from three vaccine candidates currently in Phase 3 trials have shown an efficacy of more than 90% against the development of symptomatic COVID-19. While these results are promising, all vaccines are in relatively early stages of testing. A comprehensive and transparent roadmap is urgently needed, to determine how limited doses of the first vaccines to be licensed will be distributed, together with which groups will initially be prioritized.

New study on the risk of Plasmodium vivax parasitaemia after Plasmodium falciparum malaria

@Oxford MORU Publication Research

A new study quantifying the high risk of Plasmodium vivax parasitaemia after treatment of Plasmodium falciparum malaria aims to identify populations in which a policy of universal radical cure, combining artemisinin-based combination therapy with a hypnozoitocidal antimalarial drug, would be most beneficial.